Accession Number:

ADA537750

Title:

High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-Blind Randomized Placebo Controlled Clinical Trial

Descriptive Note:

Journal article

Corporate Author:

NAVAL MEDICAL CENTER SAN DIEGO CA

Report Date:

2011-02-15

Pagination or Media Count:

10.0

Abstract:

Antiretroviral therapy ART has transformed our clinical approach to human immunodeficiency virus HIV infection. Despite substantial advances in the management of HIV infection, concerns about transmitted drug resistance, ART-related toxic effects, and the consequences of chronic inflammation persist, emphasizing the need for ongoing research into alternate therapeutic targets and strategies to modulate the chronic immune activationinflammation observed in this disease 13. Strategies that block key interactions between the host and the virus, including those that target lipid rafts, are an area of interest. Lipid rafts are plasma membrane microdomains rich in sphingolipids and cholesterol that play a critical role in the replication of HIV type 1 HIV-1 4, 5. In vitro models suggest that disruption of lipid rafts with cholesterol-depleting agents, such as 3-hydroxy-3-methyl-glutaryl-coenzyme A HMG-CoA reductase inhibitors statins, reduces HIV-1 particle production 5.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE